tiprankstipranks
Trending News
More News >
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Revenue

Compare
1 Followers

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Revenue

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had a revenue of 205.25M in the quarter ending Jun 30, 2024, with 0.00%. This bring the company's revenue in the last twelve months to 800.58M, Decreased 5.51%. In the fiscal year ending Dec 31, 2024, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had annual revenue of 980.45M with 36.76% growth.
Revenue (ttm)
800.58M
Revenue Growth
34.39%
P/S Ratio
8.91
Revenue/Employee
HK$877,756
Employees
1,117
Market Cap
HK$8.73B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
980.45M263.54M+36.76%
Dec 31, 2023
716.91M183.03M+34.28%
Dec 31, 2022
533.88M179.33M+50.58%
Dec 31, 2021
354.56M101.01M+39.84%
Dec 31, 2020
253.54M
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis